ASCO 2025 Plenary - MATTERHORN
Update: 2025-07-07
Description
This week’s episode will be focusing on one of the GI plenary session abstracts presented at the ASCO Annual Meeting 2025, the MATTERHORN trial: phase 3 durvalumab + FLOT which is 5FU leucovorin, oxaliplatin and docetaxel in resectable gastric or GE junction CA.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
